CSL Limited (ASX:CSL; USOTC:CSLLY) - CSL has appointed Ms Joy Linton, a well-respected global leader with extensive strategic and financial experience as Chief Financial Officer (CFO.) Ms Linton will be based at CSL’s Head Office in Melbourne and will join CSL’s Global Leadership Group. As previously announced in June, David Lamont will leave CSL to pursue a career opportunity with another global Australian Securities Exchange (ASX) listed company.
CSL’s Chief Executive Officer and Managing Director Mr Paul Perreault said “Joy has a demonstrated track record of success as a global CFO and she brings key leadership skills that will continue to drive our disciplined financial management, a hallmark of CSL’s sustained success. She possesses more than 30 years of experience in complex, highly regulated businesses across healthcare and other industries and we welcome her to CSL.”
Ms Linton, 54, most recently held the role as CFO and Executive Director at Bupa, a global health insurance company based in the United Kingdom, and earlier served as the General Manager of Health Services for Bupa U.K.
At CSL, Ms Linton will be responsible for managing the financial aspects of the company’s strategy and she will serve as the company’s chief financial steward. Her accountabilities will include financial planning, reporting, capital management, tax, treasury, investor relations and leading the global Finance function.
An Australian citizen, Ms Linton earned a Bachelor of Commerce Degree from the University of Melbourne and is a Fellow of the Financial Services Institute of Australasia and a graduate member of the Australian Institute of Company Directors.
“I am incredibly excited to be returning to Australia to join CSL,” Ms Linton said. “I look forward to collaborating with CSL’s internal and external stakeholders in these difficult times and beyond, to continue CSL’s work in delivering on the promise of innovative medicines to treat patients and protect public health around the world.”
CSL (ASX:CSL) is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL — including our two businesses, CSL Behring and Seqirus - provides life-saving products to more than 70 countries and employs 27,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For more information about CSL Limited, visit www.csl.com